Renee D. Gala - 28 May 2026 Form 4 Insider Report for DEXCOM INC (DXCM)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
01 Jun 2026, 17:34:19 UTC
Prior SEC filing
09 Mar 2026
Next SEC filing
05 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Renee D. Gala

Key filing fact

Renee D. Gala filed Form 4 for DEXCOM INC (DXCM) on 01 Jun 2026.

Key facts

  • This page summarizes Renee D. Gala's Form 4 filing for DEXCOM INC (DXCM).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 01 Jun 2026, 17:34.

Change

  • Previous filing in this sequence was filed on 09 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001607737 Primary reporting owner

GALA RENEE D

Relationship
Director
Address
6340 SEQUENCE DRIVE, SAN DIEGO
Signature
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Renee D. Gala
Signature date
01 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DXCM transaction

Common Stock

Award

Transaction value
Shares
+5,605
Change %
+81%
Price
$0.000000*
Shares after
12,486
Date
28 May 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

Footnote F2

Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .